Steris (NYSE:STE) received a $102.00 target price from stock analysts at Northcoast Research in a report issued on Thursday. The firm currently has a “buy” rating on the medical equipment provider’s stock. Northcoast Research’s price objective points to a potential upside of 18.76% from the company’s previous close.
A number of other research firms have also recently issued reports on STE. KeyCorp reaffirmed an “overweight” rating and issued a $101.00 price target (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research raised shares of Steris from a “hold” rating to a “buy” rating and set a $103.00 price target for the company in a report on Tuesday, January 23rd. Raymond James Financial raised their price target on shares of Steris from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, October 16th. Finally, TD Securities raised their price target on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $84.40.
Steris (NYSE STE) traded down $0.28 during midday trading on Thursday, hitting $85.89. 424,578 shares of the company’s stock were exchanged, compared to its average volume of 377,873. The stock has a market capitalization of $7,290.00, a PE ratio of 30.43 and a beta of 1.22. Steris has a fifty-two week low of $66.36 and a fifty-two week high of $93.71. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48.
In other news, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Sudhir K. Pahwa sold 2,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $92.09, for a total transaction of $184,180.00. The disclosure for this sale can be found here. Company insiders own 2.55% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its stake in shares of Steris by 1.5% in the second quarter. Ameritas Investment Partners Inc. now owns 25,416 shares of the medical equipment provider’s stock worth $2,071,000 after acquiring an additional 379 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in shares of Steris by 5.9% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 9,817 shares of the medical equipment provider’s stock worth $859,000 after acquiring an additional 547 shares during the period. Comerica Bank increased its stake in shares of Steris by 0.9% in the fourth quarter. Comerica Bank now owns 68,219 shares of the medical equipment provider’s stock worth $6,255,000 after acquiring an additional 628 shares during the period. Crossmark Global Holdings Inc. increased its stake in shares of Steris by 6.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 9,810 shares of the medical equipment provider’s stock worth $858,000 after acquiring an additional 630 shares during the period. Finally, Swiss National Bank increased its stake in shares of Steris by 0.6% in the third quarter. Swiss National Bank now owns 142,255 shares of the medical equipment provider’s stock worth $12,575,000 after acquiring an additional 800 shares during the period. Hedge funds and other institutional investors own 89.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Steris (STE) PT Set at $102.00 by Northcoast Research” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/08/steris-ste-pt-set-at-102-00-by-northcoast-research.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.